Treatment of severe infections caused by Staphylococcus aureus: a change in the vancomycin paradigm?

Area of Science:

• Infectious Diseases
• Microbiology
• Critical Care Medicine

Background:

• Staphylococcus aureus is a leading cause of intensive care unit (ICU) infections, often exhibiting high mortality.
• Methicillin resistance in S. aureus (MRSA) is prevalent globally (>50% in many regions), making vancomycin the preferred antibiotic.
• While vancomycin resistance is common in Enterococcus, it remains infrequent in S. aureus.

Discussion:

• Recent years have seen an increase in vancomycin treatment failures for S. aureus infections, even in strains considered susceptible.
• This phenomenon challenges the established treatment protocols and understanding of vancomycin efficacy against S. aureus.
• Investigating the underlying mechanisms of these treatment failures is crucial for effective patient management.

Key Insights:

• Vancomycin efficacy is being questioned due to treatment failures in susceptible S. aureus strains.
• The rise in treatment failures necessitates a re-evaluation of current therapeutic paradigms.
• Understanding the reasons behind these failures is critical for optimizing S. aureus infection management.

Outlook:

• Further research is needed to elucidate the mechanisms behind vancomycin treatment failures.
• Development of alternative or adjunctive therapies may be required for challenging S. aureus infections.
• This review aims to provide a comprehensive overview of the current challenges and future directions in managing S. aureus infections.